



F-star Finalist in Three Categories of 2017 Biotech and Money Awards

Cambridge, UK, 22 June 2017 – F-star, a biopharmaceutical company developing novel bispecific antibodies, announces it is a finalist in three categories for the Biotech and Money 2017 Awards.

The Awards celebrate funding, finance and investment successes in the UK Life Sciences over the past year. F-star is a finalist in the following categories:

- **UK Growth Life Science Company of the Year (more than three years old)**
- **UK Life Science Deal of the Year (along with Merck)**
- **UK Life Science CEO of the Year**

The “**Deal of the Year**” nomination is for F-star’s recent deal with Merck to develop and commercialise five bispecific next-generation immuno-oncology antibodies, which further validates the potential of F-star’s technology. This innovative transaction provides Merck with an exclusive option to acquire F-star Delta, the fourth asset-centric vehicle of the F-star family. Merck will pay a total of \$115m in upfront, R&D funding and milestone payments over the first two years. With subsequent option exercise and milestone payments the potential deal value is \$1B.

“**Company of the Year**” and “**CEO of the Year**” nominations recognize the significant progress the company has made in the last 12 months. In addition to the recent agreement with Merck, F-star has entered into a collaboration with Denali to research and develop antibodies for the delivery of medicines into the central nervous system. Both deals are held in separate entities (Delta for the former and Gamma for the latter) underlining F-star’s innovative asset-centric business model. John Haurum, CEO, has steered the Company R&D and BD strategy since 2012, and with over 15 years in leading antibody-based drug discovery and development has progressed multiple assets into clinical development and has managed numerous successful BD transactions.

Voting is now [open](#). The winners in each category are determined 50% by this online voting and 50% by a live vote on the night of the Awards dinner, which is held in London on 14 September.

Details of the Awards ceremony are here: [Assembly and Awards Gala Dinner](#)

-Ends-

For further information, please contact:

At F-star	Media enquiries
Pierre Peotta Communications Manager +44 (0)7392 080 279 pierre.peotta@f-star.com	Instinctif Partners (EU & RoW) Sue Charles/Daniel Gooch +44 (0)20 7866 7905 F-star@instinctif.com Lazar Partners (USA) Glenn Silver +1 (0)212 867 1762 Gsilver@lazarpartners.com

About F-star

F-star is a clinical-stage biopharmaceutical company developing bispecific antibody immuno-oncology products selected for their potential to transform the treatment of cancer. Through the application of its highly efficient Modular Antibody Technology™ platform, F-star is the only biotechnology company able to rapidly create bispecific antibodies with properties virtually identical to a typical antibody. This offers unprecedented ease in the discovery, development, and manufacturing of bispecific antibody products. F-star has currently one programme in the clinic with a second immuno-oncology programme heading toward IND. The Company has built a comprehensive IP estate around its technology and product pipeline, with over 50 patent applications filed and over 25 granted patents.

F-star's management team has a well-established track record in building successful biotech companies, and developing biologics. The team is advised by a world-leading scientific advisory board and a highly experienced board of directors. The strength of the technology and programmes has been leveraged through partnerships with leading biopharmaceutical companies including AbbVie, Merck KGaA and Denali Therapeutics. F-star has raised close to \$200M in non-dilutive capital and revenues. The company currently employs over 80 people at its research site in Cambridge, UK.

For more information visit www.f-star.com

About Biotech and Money Awards 2017

Biotech and Money Assembly and Awards is a 250 person Gala Dinner celebrating the UK's funding, finance and investment successes in the sector over the last 12 months. Leading lights and emerging stars, C-suite executives, impactful investors and powerful KOLs in the sector will be celebrating at one of London's finest banqueting halls; Merchant Taylors Hall on 14th September 2017, from 6pm-11pm.

For more information, please visit the website: <http://www.biotechandmoney.com/gala-dinner>